Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Extra Space Storage, Inc. (EXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Extra Space Storage, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Extra Space Storage, Inc. trades at $145.35 (market cap $30.74B). The key difference: Extra Space Storage, Inc. is far larger — about 3.8× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Extra Space Storage, Inc. pays a 4.45% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | EXR | |
|---|---|---|
Market Cap | $8.04B | $30.74B |
Sector | Health | Real Estate |
52-Week High | $339.75 | $152.75 |
52-Week Low | $241.71 | $126.67 |
Enterprise Value | $7.85B | $44.54B |
Dividend Yield | — | 4.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
EXR trades at $145.32, up 0.94% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating estimates at $1.14 versus $1.12 expected, maintaining a three-quarter beat streak. Revenue grew to $3.38B in 2025 with robust 70.63% gross margins. Analyst consensus is mixed with 12 Buy and 16 Hold ratings, targeting $155.88 average price. Recent $550 million debt issuance supports expansion amid steady operational cash flow of $1.85B.
Outlook remains stable with resilient self-storage demand offset by debt concerns. The 6.92% ROE and 32.66 P/E suggest fair valuation. Key risks include rising expenses and competitive supply pressures. Institutional sentiment leans cautious despite consistent dividend payments, with technical resistance near $146 limiting near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →
